Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 10/20 | 0.59 |
| ▸ | DPP3 | Q9NY33 | 3/20 | 0.54 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | MC4R | P32245 | 1/20 | 0.51 |
| ▸ | MC5R | P33032 | 1/20 | 0.51 |
| ▸ | MC3R | P41968 | 1/20 | 0.51 |
| ▸ | MC1R | Q01726 | 1/20 | 0.51 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31247508 | 0.86 | CXCL8 (0.55) | CXCL8DPP3CAPN1CTSB | |
| SCHEMBL10599944 | 0.86 | DPP3 (0.57) | CXCL8DPP3KISS1R | |
| SCHEMBL10599958 | 0.86 | DPP3 (0.57) | CXCL8DPP3KISS1R | |
| SCHEMBL30702429 | 0.86 | CXCL8 (0.55) | CXCL8CAPN1CTSB | |
| SCHEMBL29695397 | 0.86 | KISS1R (0.56) | CXCL8DPP3KISS1R | |
| SCHEMBL16891329 | 0.85 | CXCL8 (0.57) | CXCL8DPP3 | |
| SCHEMBL29855998 | 0.85 | DPP3 (0.60) | CXCL8DPP3CAPN1CTSBKISS1R | |
| SCHEMBL31247348 | 0.85 | CAPN1 (0.57) | CXCL8DPP3CAPN1CTSBMC4R | |
| SCHEMBL31575692 | 0.85 | CXCL8 (0.58) | CXCL8DPP3CAPN1CTSBKISS1R | |
| SCHEMBL30949447 | 0.85 | CXCL8 (0.63) | CXCL8CAPN1CTSBKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | LONGEVITY BIOTECH, INC. | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374689-A1 | HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME | SCTR, GIPR, APLNR | CXCL8 2162/4885DPP3 232/4885CAPN1 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.